GB0715937D0 - Method of treatment og duchenne muscular dystrophy - Google Patents

Method of treatment og duchenne muscular dystrophy

Info

Publication number
GB0715937D0
GB0715937D0 GBGB0715937.9A GB0715937A GB0715937D0 GB 0715937 D0 GB0715937 D0 GB 0715937D0 GB 0715937 A GB0715937 A GB 0715937A GB 0715937 D0 GB0715937 D0 GB 0715937D0
Authority
GB
United Kingdom
Prior art keywords
treatment
muscular dystrophy
duchenne muscular
duchenne
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0715937.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Vastox PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vastox PLC filed Critical Vastox PLC
Priority to GBGB0715937.9A priority Critical patent/GB0715937D0/en
Publication of GB0715937D0 publication Critical patent/GB0715937D0/en
Priority to MX2009011916A priority patent/MX2009011916A/es
Priority to RU2009141831/04A priority patent/RU2009141831A/ru
Priority to TW097131010A priority patent/TW200911767A/zh
Priority to EP08785566A priority patent/EP2188270A2/en
Priority to CN200880015864A priority patent/CN101679323A/zh
Priority to PCT/EP2008/006719 priority patent/WO2009021749A2/en
Priority to JP2010520499A priority patent/JP2010535830A/ja
Priority to ARP080103560A priority patent/AR068810A1/es
Priority to JP2010520498A priority patent/JP2010535829A/ja
Priority to US12/599,970 priority patent/US8138351B2/en
Priority to AU2008286325A priority patent/AU2008286325A1/en
Priority to PCT/EP2008/006718 priority patent/WO2009021748A2/en
Priority to MX2009011967A priority patent/MX2009011967A/es
Priority to BRPI0811315-7A2A priority patent/BRPI0811315A2/pt
Priority to CA002685939A priority patent/CA2685939A1/en
Priority to US12/192,053 priority patent/US20090048314A1/en
Priority to PE2008001385A priority patent/PE20090604A1/es
Priority to CN2008800158003A priority patent/CN101896475A/zh
Priority to BRPI0811548-6A2A priority patent/BRPI0811548A2/pt
Priority to AU2008286324A priority patent/AU2008286324A1/en
Priority to CA002685590A priority patent/CA2685590A1/en
Priority to CL2008002391A priority patent/CL2008002391A1/es
Priority to KR1020097023605A priority patent/KR20100075777A/ko
Priority to EP08785565A priority patent/EP2176246A2/en
Priority to IL201908A priority patent/IL201908A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GBGB0715937.9A 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy Ceased GB0715937D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy
EP08785565A EP2176246A2 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of duchenne muscular dystrophy
PCT/EP2008/006718 WO2009021748A2 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of duchenne muscular dystrophy
BRPI0811315-7A2A BRPI0811315A2 (pt) 2007-08-15 2008-08-14 Processo para a preparação de um composto
TW097131010A TW200911767A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
EP08785566A EP2188270A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy
CN200880015864A CN101679323A (zh) 2007-08-15 2008-08-14 用于治疗杜兴氏肌营养不良症的化合物的多晶型体
PCT/EP2008/006719 WO2009021749A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy
JP2010520499A JP2010535830A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用化合物の製造
ARP080103560A AR068810A1 (es) 2007-08-15 2008-08-14 Formas polimorficas de 5-(etilsulfonil)-2-(naftalen-2-il)benzo(d)oxazol, metodos para su preparacion y composiciones farmaceuticas que las comprenden
JP2010520498A JP2010535829A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体
US12/599,970 US8138351B2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
AU2008286325A AU2008286325A1 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of Duchenne muscular dystrophy
MX2009011916A MX2009011916A (es) 2007-08-15 2008-08-14 Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.
MX2009011967A MX2009011967A (es) 2007-08-15 2008-08-14 Formas polimorficas de un compuesto para el tratamiento de la distrofia muscular de duchenne.
RU2009141831/04A RU2009141831A (ru) 2007-08-15 2008-08-14 Лечение мышечной дистрофии дюшенна
CA002685939A CA2685939A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
US12/192,053 US20090048314A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
PE2008001385A PE20090604A1 (es) 2007-08-15 2008-08-14 Tratamiento de distrofia muscular de duchenne
CN2008800158003A CN101896475A (zh) 2007-08-15 2008-08-14 用于治疗杜兴氏肌营养不良的化合物的制备
BRPI0811548-6A2A BRPI0811548A2 (pt) 2007-08-15 2008-08-14 Forma polimórfica de um composto, composição farmacêutica, e, processo para sintetizar uma forma polimórfica de um composto
AU2008286324A AU2008286324A1 (en) 2007-08-15 2008-08-14 Polymorphs of a compound for the treatment of Duchenne muscular dystrophy
CA002685590A CA2685590A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
CL2008002391A CL2008002391A1 (es) 2007-08-15 2008-08-14 Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne.
KR1020097023605A KR20100075777A (ko) 2007-08-15 2008-08-14 뒤시엔느 근이영양증의 치료를 위한 화합물의 다형체
IL201908A IL201908A0 (en) 2007-08-15 2009-11-03 Polymorphs of a compound for the treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0715937D0 true GB0715937D0 (en) 2007-09-26

Family

ID=38566447

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0715937.9A Ceased GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Country Status (17)

Country Link
US (2) US8138351B2 (cg-RX-API-DMAC10.html)
EP (2) EP2176246A2 (cg-RX-API-DMAC10.html)
JP (2) JP2010535830A (cg-RX-API-DMAC10.html)
KR (1) KR20100075777A (cg-RX-API-DMAC10.html)
CN (2) CN101679323A (cg-RX-API-DMAC10.html)
AR (1) AR068810A1 (cg-RX-API-DMAC10.html)
AU (2) AU2008286324A1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0811548A2 (cg-RX-API-DMAC10.html)
CA (2) CA2685939A1 (cg-RX-API-DMAC10.html)
CL (1) CL2008002391A1 (cg-RX-API-DMAC10.html)
GB (1) GB0715937D0 (cg-RX-API-DMAC10.html)
IL (1) IL201908A0 (cg-RX-API-DMAC10.html)
MX (2) MX2009011916A (cg-RX-API-DMAC10.html)
PE (1) PE20090604A1 (cg-RX-API-DMAC10.html)
RU (1) RU2009141831A (cg-RX-API-DMAC10.html)
TW (1) TW200911767A (cg-RX-API-DMAC10.html)
WO (2) WO2009021749A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707719A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
MX2018012018A (es) * 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
WO2018236879A1 (en) 2017-06-19 2018-12-27 University Of Maryland, Baltimore INHIBITORS OF MICROTUBULAR POLYMERIZATION PRODRUGS AND METHODS OF USE

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (cg-RX-API-DMAC10.html) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
ES2092080T3 (es) * 1991-08-08 1996-11-16 Ciba Geigy Ag Colorantes, procedimiento para su obtencion y su utilizacion.
ES2157268T5 (es) * 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
EP0767809B1 (en) * 1994-06-30 2004-01-21 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
US5596025A (en) * 1994-06-30 1997-01-21 Minnesota Mining And Manufacturing Company Dental impression material with cure-indicating dye
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
EP1177179A1 (de) * 1999-05-07 2002-02-06 Basf Aktiengesellschaft Benzoheterocyclylcyclohexenone und ihre verwendung als herbizide
WO2000068228A1 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft 4-(3',4'-heterocyclylbenzoyl) pyrazole als herbizide
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
AU7320100A (en) * 1999-09-24 2001-04-24 Ono Pharmaceutical Co. Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
EP1881050B1 (en) * 2000-11-30 2013-01-09 Canon Kabushiki Kaisha Luminescence device and display apparatus
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
US20040248957A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005029187A1 (en) * 2003-09-22 2005-03-31 Agfa-Gevaert Photopolymerizable composition.
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
AU2005211255A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006019270A1 (en) * 2004-08-19 2006-02-23 Lg Chem. Ltd. Organic light-emitting device comprising buffer layer and method for fabricating the same
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
CA2630806C (en) * 2005-12-02 2015-01-06 Sachem, Inc. Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
BRPI0707719A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
EP2188270A2 (en) 2010-05-26
EP2176246A2 (en) 2010-04-21
BRPI0811315A2 (pt) 2015-01-27
WO2009021748A3 (en) 2009-04-02
RU2009141831A (ru) 2011-05-20
MX2009011967A (es) 2009-11-19
IL201908A0 (en) 2010-06-16
AU2008286325A1 (en) 2009-02-19
MX2009011916A (es) 2009-11-18
JP2010535830A (ja) 2010-11-25
US20090048314A1 (en) 2009-02-19
CN101896475A (zh) 2010-11-24
TW200911767A (en) 2009-03-16
AU2008286324A1 (en) 2009-02-19
JP2010535829A (ja) 2010-11-25
CA2685590A1 (en) 2009-02-19
US8138351B2 (en) 2012-03-20
AR068810A1 (es) 2009-12-09
US20100267961A1 (en) 2010-10-21
CA2685939A1 (en) 2009-02-19
PE20090604A1 (es) 2009-05-16
WO2009021749A8 (en) 2009-09-11
WO2009021748A2 (en) 2009-02-19
WO2009021749A3 (en) 2009-04-02
CL2008002391A1 (es) 2009-05-22
CN101679323A (zh) 2010-03-24
KR20100075777A (ko) 2010-07-05
WO2009021749A2 (en) 2009-02-19
BRPI0811548A2 (pt) 2014-11-18

Similar Documents

Publication Publication Date Title
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of Duchenne muscular dystrophy
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
ZA200806630B (en) Method of treatment for muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
SI2170396T1 (sl) Kombinacije zdravil za zdravljenje duchennove mišične distrofije
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
ZA200806986B (en) Treatment of duchenne muscular dystrophy
ZA200905470B (en) Method for thickening and thickening apparatus
GB0817067D0 (en) Intestinal treatment
IL201908A0 (en) Polymorphs of a compound for the treatment of duchenne muscular dystrophy
PL2318573T3 (pl) Sposób obróbki przeciwkorozyjnej
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0614690D0 (en) Method of treatment of duchenne muscular dystrophy
GB0602767D0 (en) Treatment of muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0619282D0 (en) Treatment of duchenne muscular dystrophy
GB0617740D0 (en) Treatment of duchenne muscular dystrophy
GB0623983D0 (en) Treatment of duchenne muscular dystrophy
GB0619283D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)